Article

KalVista wins grant for DME treatment

KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Related Content
AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
May 16th 2025

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System
May 15th 2025

LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Nicox releases results from Whistler phase 3b trial in IOP lowering eye drops
May 15th 2025

Nicox releases results from Whistler phase 3b trial in IOP lowering eye drops

Structure-function link between ellipsoid zone integrity features and visual acuity in eyes with GA
May 15th 2025

Structure-function link between ellipsoid zone integrity features and visual acuity in eyes with GA

© 2025 MJH Life Sciences

All rights reserved.